J. Randolph Hecht

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +13

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac et al. · Journal of Clinical Oncology · 2008 · 852 citations · Full text

Medicine, Oncology, Pharmacology +15

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

John J. Rinehart, Alex A. Adjei, Patricia LoRusso et al. · Journal of Clinical Oncology · 2004 · 639 citations

Medicine, Oncology, Pharmacology +16

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer

Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus et al. · Journal of Clinical Oncology · 2014 · 632 citations

Medicine, Oncology, Pharmacology +12

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <i>In vitro</i> and <i>In vivo</i>

Zev A. Wainberg, Adrian Anghel, Amrita Desai et al. · Clinical Cancer Research · 2010 · 211 citations

Medicine, Oncology, Pharmacology +16